Results 81 to 90 of about 3,802,616 (346)

Correction: Mehrling, T.; et al. Challenges in Optimising the Successful Construction of Antibody Drug Conjugates in Cancer Therapy. Antibodies 2018, 7, 11

open access: yesAntibodies, 2018
The Conflict of Interest section of the published paper [1] has been updated as follows: [...]
Thomas Mehrling   +2 more
doaj   +1 more source

Structure, Function, and Therapeutic Use of IgM Antibodies

open access: yesAntibodies, 2020
Natural immunoglobulin M (IgM) antibodies are pentameric or hexameric macro-immunoglobulins and have been highly conserved during evolution. IgMs are initially expressed during B cell ontogeny and are the first antibodies secreted following exposure to ...
B. Keyt   +4 more
semanticscholar   +1 more source

Novel and unscrutinized immune entities of the zebrafish gut

open access: yesFEBS Letters, EarlyView.
Understudied cells of the zebrafish immune system include bona fide immune cells and epithelial (‐derived) cells with immune functions. Research focusing on zebrafish cells which demonstrate similarities to mammalian immune cell counterparts may help us understand the pathologies in which they are implicated. Currently available and advanced tools make
Audrey Inge Schytz Andersen‐Civil   +5 more
wiley   +1 more source

Enzyme-linked immunosorbent assay, Elisa. 3. Quantitation of specific antibodies by enzyme-labeled anti-immunoglobulin in antigen-coated tubes.

open access: yesJournal of Immunology, 1972
A sensitive and simple method for the quantitative determination of antibodies is reported. Tubes coated with antigen are incubated with antiserum followed by an enzyme-labeled preparation of anti-immunoglobulin. The enzyme remaining in the tubes after
E. Engvall, P. Perlmann
semanticscholar   +1 more source

Imeglimin attenuates liver fibrosis by inhibiting vesicular ATP release from hepatic stellate cells

open access: yesFEBS Letters, EarlyView.
Imeglimin, at clinically relevant concentrations, inhibits vesicular ATP accumulation and release from hepatic stellate cells, thereby attenuating purinergic signaling and reducing fibrogenic activation. This mechanism reveals a newly identified antifibrotic action of imeglimin beyond glycemic control.
Seiji Nomura   +8 more
wiley   +1 more source

Cancer cell death induced by the NAD antimetabolite Vacor discloses the antitumor potential of SARM1

open access: yesFEBS Letters, EarlyView.
Vacor, a compound converted into the toxic metabolite Vacor adenine dinucleotide (VAD) by the nicotinamide salvage pathway enzymes NAMPT and NMNAT2, exhibits antitumor activity by inducing rapid and complete NAD depletion. We report that Vacor toxicity is limited to cell lines expressing high levels of SARM1, a NAD glycohydrolase.
Giuseppe Ranieri   +5 more
wiley   +1 more source

mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants

open access: yesNature, 2021
Zijun Wang   +33 more
semanticscholar   +1 more source

Multidimensional OMICs reveal ARID1A orchestrated control of DNA damage, splicing, and cell cycle in normal‐like and malignant urothelial cells

open access: yesMolecular Oncology, EarlyView.
Loss of the frequently mutated chromatin remodeler ARID1A, a subunit of the SWI/SNF cBAF complex, results in less open chromatin, alternative splicing, and the failure to stop cells from progressing through the cell cycle after DNA damage in bladder (cancer) cells. Created in BioRender. Epigenetic regulators, such as the SWI/SNF complex, with important
Rebecca M. Schlösser   +11 more
wiley   +1 more source

Unveiling novel insights into human IL-6 − IL-6R interaction sites through 3D computer-guided docking and systematic site mutagenesis

open access: yesScientific Reports
The cytokine interleukin-6 (IL-6) plays a crucial role in autoimmune and inflammatory diseases. Understanding the precise mechanism of IL-6 interaction at the amino acid level is essential to develop IL-6-inhibiting compounds.
Kaitong Li   +16 more
doaj   +1 more source

Antibodies to watch in 2020

open access: yesmAbs, 2019
This 2020 installment of the annual ‘Antibodies to Watch’ series documents the antibody therapeutics approved in 2019 and in regulatory review in the United States or European Union, as well as those in late-stage clinical studies, as of November 2019 ...
H. Kaplon   +3 more
semanticscholar   +1 more source

Home - About - Disclaimer - Privacy